Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Maximal virologic suppression reported at 1 year in phase IIb extension study of PRO-140

Dec. 2, 2015

Mylan outlines plans for antiretroviral treatment TLE-400

Dec. 2, 2015

Shionogi presents anti-HIV agents

Nov. 27, 2015

Gilead Sciences' Genvoya approved in E.U. for HIV-1 infection

Nov. 24, 2015

NIAID and GSK collaborate on broadly neutralizing antibody strategy for HIV infection

Nov. 23, 2015

FDA approves Genvoya single-tablet regimen for HIV-1

Nov. 6, 2015

ViiV Healthcare and Janssen report results from injectable cabotegravir regimen study

Nov. 5, 2015

Bristol-Myers Squibb reports HIV maturation inhibitors

Oct. 27, 2015

CHMP recommends extension of approval of rilpivirine to adolescents with HIV infection

Oct. 27, 2015

Genvoya noninferior to Stribild in phase III studies in treatment-naive adults with HIV infection

Oct. 23, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...